Mycobacterium Tuberculosis-Specific T-Cell Responses Are Impaired During Late Pregnancy With Elevated Biomarkers of Tuberculosis Risk Postpartum
Overview
Authors
Affiliations
Background: Pregnancy is a risk factor for progression from latent tuberculosis infection to symptomatic tuberculosis. However, how pregnancy influences T-cell responses to Mycobacterium tuberculosis is unknown.
Methods: We measured M. tuberculosis-specific cytokines, T-cell memory markers, and overall CD4+ and CD8+ T-cell activation by flow cytometry from 49 women (18 with and 31 without HIV) who became pregnant while enrolled in a randomized controlled trial of preexposure prophylaxis for HIV. We analyzed data using COMPASS, an established statistical method for evaluating overall antigen-specific T-cell responses.
Results: Pregnant women with latent tuberculosis infection demonstrated significantly diminished M. tuberculosis-specific CD4+ cytokine responses in the third trimester (COMPASS polyfunctional score [PFS], 0.07) compared before (PFS, 0.15), during (PFS, 0.13 and 0.16), and after pregnancy (PFS, 0.14; P = .0084, Kruskal-Wallis test). Paradoxically, M. tuberculosis-specific CD8+ cytokines and nonspecifically activated T-cells increased during late pregnancy. Nonspecific T-cell activation, a validated biomarker for progression from latent tuberculosis infection to tuberculosis disease, increased in latent tuberculosis infection-positive women postpartum, compared with latent tuberculosis infection-negative women.
Conclusions: Pregnancy-related functional T-cell changes were most pronounced during late pregnancy. Both M. tuberculosis-specific T-cell changes during pregnancy and increases in immune activation postpartum may contribute to increased risk for tuberculosis progression.
Clinical Trials Registration: NCT0557245.
Immune-neuroendocrine reactivity and features of tuberculosis in pregnancy.
Starshinova A, Churilov L, Kudryavtsev I, Rubinstein A, Belyaeva E, Kulpina A Front Med (Lausanne). 2025; 12:1503402.
PMID: 39981081 PMC: 11840263. DOI: 10.3389/fmed.2025.1503402.
Saha A, Escudero J, Layouni T, Mecha J, Maleche-Obimbo E, Matemo D Open Forum Infect Dis. 2025; 12(2):ofaf067.
PMID: 39981072 PMC: 11842132. DOI: 10.1093/ofid/ofaf067.
Discordance of 3rd and 4th generation QuantiFERON-TB Gold assays by pregnancy stages in India.
Kulkarni V, Alexander M, Bhosale R, Jain D, Deshpande P, Gitlin E J Clin Tuberc Other Mycobact Dis. 2025; 38:100504.
PMID: 39758562 PMC: 11697401. DOI: 10.1016/j.jctube.2024.100504.
Li S, Wang J, Yu H, Huang H, Lu S, Wang X Infect Drug Resist. 2024; 17:5463-5468.
PMID: 39711830 PMC: 11663480. DOI: 10.2147/IDR.S478844.
The effect of antenatal isoniazid preventive therapy on birth outcomes in Western Kenya.
Quincer E, Lyland A, Onyango D, LaCourse S, Figueroa J, John-Stewart G Int J Tuberc Lung Dis. 2023; 27(12):906-911.
PMID: 38042967 PMC: 11057228. DOI: 10.5588/ijtld.23.0134.